| History of Lung Transplantation: Pioneering Surgery to Established Therapy
A. Haverich (Hannover, Germany) | |  | |  | |  |  | | | |
|
| The key elements of a Lung Transplant service
P. Corris (Newcastle, United Kingdom) | | | | | | | | | | |
|
| Referral criteria and candidate selection in CF and Bronchiectasis
L. Eriksson (Lund, Sweden) | | | | | | | | | | |
|
| Referral criteria and candidate selection in ILD and COPD
F. Meloni (Pavia, Italy) | | | | | | | | | | |
|
| Referral criteria and candidate selection in PH and CHD
G. Verleden (Leuven, Belgium) | | | | | | | | | | |
|
| Pushing the boundaries of donor acceptability
A. Fisher (Newcastle, United Kingdom) | | | | | | | | | | |
|
| Non-Heart beatin lung donors - Hope for the future
D. Van Raemdonck (Leuven, Belgium) | | | | | | | | | | |
|
| Increasing donation rates
M. Anile (Roma, Italy) | | | | | | | | | | |
|
| Candidate Selection
A. Boehler (Zurich, Switzerland) | | | | | | | | | | |
|
| Donor Selection
M. Strueber (Hannover, Germany) | | | | | | | | | | |
|
| Choice of Transplant procedure
M. Anile (Roma, Italy) | | | | | | | | | | |
|
| Primary graft dysfunction - pathophysiology
D. Van Raemdonck (Leuven, Belgium) | | | | | | | | | | |
|
| Primary graft dysfunction - clinical management
M. Strueber (Hannover, Germany) | | | | | | | | | | |
|
| Acute rejection - identification and management
F. Meloni (Pavia, Italy) | | | | | | | | | | |
|
| Cytomegalovirus
E. Verschuuren (Groningen, The Netherlands) | | | | | | | | | | |
|
| Aspergillus and other fungi
G. Verleden (Leuven, Belgium) | | | | | | | | | | |
|
| Multiresistant bacterial infections
A. Fisher (Newcastle, United Kingdom) | | | | | | | | | | |
|
| The role of the multidisciplinary team in a successful programme
A. Boehler (Zurich, Switzerland) | | | | | | | | | | |
|
| The process of establishing a lung transplant programme
T. Grodzki (Szczecin, Poland) | | | | | | | | | | |
|
| Induction therapies in the 21st Century
L. Eriksson (Lund, Sweden) | | | | | | | | | | |
|
| Calcineurin inhibitors: Friend of Foe?
G. Verleden (Leuven, Belgium) | | | | | | | | | | |
|
| Newer immunosuppressants: MMF and Sirolimus/Everolimus
P. Corris (Newcastle, United Kingdom) | | | | | | | | | | |
|
| New insights into BOS/OB aetiology
A. Fisher (Newcastle, United Kingdom) | | | | | | | | | | |
|
| Diagnosing BOS/OB
A. Boehler (Zurich, Switzerland) | | | | | | | | | | |
|
| Therapeutic options for BOS/OB
P. Corris (Newcastle, United Kingdom) | | | | | | | | | | |
|
| Renal dysfunction
F. Meloni (Pavia, Italy) | | | | | | | | | | |
|
| Lymphoproliferative disease and other malignancies
E. Verschuuren (Groningen, The Netherlands) | | | | | | | | | | |
|
| Quality of life in longterm survivors
L. Eriksson (Lund, Sweden) | | | | | | | | | | |
|
| Early complications
D. Van Raemdonck (Leuven, Belgium) | | | | | | | | | | |
|
| Managing BOS/OB
G. Verleden (Leuven, Belgium) | | | | | | | | | | |
|
| Infectious complications
E. Verschuuren (Groningen, The Netherlands) | | | | | | | | | | |
|